Boluoke® (lumbrokinase) is the only fully researched oral enzyme on the market supporting a healthier blood state, and it shows great promise in supporting a healthy coagulation/fibrinolysis balance in the body.

Lumbrokinase is a more potent enzyme preparation than nattokinase. One of the advantages of Boluoke® (lumbrokinase) is that it does not interfere with the clotting cascade, but instead, works by reducing fibrinogen and fibrin. Boluoke® does not affect INR or aPTT, thus is compatible with Coumadin® or heparin.

Boluoke® vs. Other Lumbrokinase Products
Comparing other lumbrokinase products to Boluoke® is like comparing apples and oranges. Boluoke®’s enzymatic strength is standardized against urokinase and t-PA. The imitation products are likely just earthworm protein extract containing little pure lumbrokinase or lumbrokinase of low enzymatic strength. Some companies are making products with 230mg to 250mg of lumbrokinase per capsule and trying to quote Boluoke®’s research as their own. Boluoke®’s capsules are of 200mg in size, and contain 20mg of lumbrokinase inside each capsule. Most of these other lumbrokinase are unable to distinguish between the weight of the capsule (i.e. 250 mg) and the active lumbrokinase per capsule (Boluoke® is 20 mg).

Boluoke® is the only fully researched oral fibrinolytic supplement on the market. Besides having in vitro studies, animal studies, toxicity studies, and pharmacokinetic studies done, Boluoke® has also been put through all phases of clinical trials (including randomized double blind controlled studies) in China. Boluoke® is the only Lumbrokinase that is backed by Phase I – III clinical trials in China, the one that is first used in hospitals in China, and covered by the Chinese National Fundamental Health Insurance.

A common question we receive is about potential side effects of Boluoke®. The earthworm has been used in Traditional Chinese Medicine for a few thousand years, and is considered to be one of the safest medicines in the traditional pharmacopoeias. In one of the largest clinic trials of Boluoke® involving 16 hospitals and 1560 patients in China, the overall adverse reaction rate was 1.92% (30 cases). 0.58% had skin itching, 0.19% had skin rash, and 1.15% had nausea or diarrhea; no hemorrhage or major side effect was reported. Again, this research pertains only to Boluoke®.

It is interesting that other lumbrokinase products cite the clinical results achieved with only Boluoke®, confusing the reader into assuming that the research was done on their formulations. However, their products may be very different, and your patients may have very different results.

On the raw material market, the price of lumbrokinase can vary by up to 15 fold, and the enzymatic strengths of various Lumbrokinase also differ greatly. In addition, lumbrokinase is a preparation containing multiple enzyme fractions, and the extraction and purification method determines the composition of the various enzyme fractions. Thus different extraction methods will produce different sub-fractions of lumbrokinase. This is the reason why Boluoke® does not significantly change prothrombin time (PT) or activated partial thromboplastin time (aPTT), while other lumbrokinase sources may significantly alter PT or aPTT as shown in studies. No other lumbrokinase product can provide you with this assurance.